Replies to post #37914 on Entest Group Inc

[JokersWild12]

Rooster, that's a he++ no on an IPO. There is already enough stock OS for all of these entities.

Zander Therapeutics Inc. is a wholly owned subsidiary of Entest BioMedical Inc. (PINKS: ENTB). David R. Koos serves as Chairman and Chief Executive Officer of Regen, Entest Biomedical, Inc. and Zander Therapeutics. So it should trade as ENTB. Lets keep it that way and with the current OS.

Next lets see the patent acceptance for Composition of Matter Patent on NR2F6 Modulating Small Molecules in Canine and Feline Applications AND a PLAN to move forward.

There are test results for animals so get on with a plan to forward the therapies and stop the floundering at these price levels.